IGF-LR3 Peptide Screening Form Template

IGF-LR3 (Insulin-like Growth Factor-1 Long R3) is a potent growth factor peptide that enhances the effects of growth hormone on muscle protein synthesis, cellular repair, and metabolic function. It is prescribed off-label through compounding pharmacies for body composition, recovery optimization, and anabolic support. Due to its insulin-like effects, careful metabolic screening is essential before initiating therapy. This form documents symptom burden and contraindications for safe patient selection.

4 sections
17 fields
HIPAA-ready
3 citations

Free Template

IGF-LR3 Peptide Screening Form

Preview Form Automate This Form
No account required to use template
Customize with your practice branding
Reviewed against HIPAA & DEA guidelines

Form Preview

This is how the form appears to patients. Customize with your practice name and branding.

Your Practice Name

IGF-LR3 Peptide Screening Form

Preview
1

General Patient Information

Please provide your personal information.

First Name

Jane

Last Name

Smith

Date of Birth

Can you confirm you are 18 years or older?

Height

e.g. 5'8"

Weight

e.g. 170 lbs

2

Medical History

Please answer all questions as accurately as possible. Your provider will review this information.

Are you actively taking any medications? If so, please list them.

List all current medications, dosages, and frequencies

Do you have any medication allergies? If so, please list them.

List all known drug allergies and reactions

Are you currently being treated or have you been treated for any medical conditions? If so, please list them.

List all current and past medical conditions

Have you had any past surgeries? If so, please list them.

List all surgeries and approximate dates

What is/was your sex assigned at birth?

Male

Emergency contact name and phone number

Name — (555) 000-0000

Mailing address

123 Main St, City, State, ZIP

Any other questions or concerns?

Optional — share anything else you'd like your provider to know

3

Symptoms

Select all symptoms that currently apply to you.

Which of the following symptoms are you experiencing?
4

Medical Conditions

Select all conditions that currently apply to you.

Do any of the following apply to you?

Preview only. Your live form will include your branding and e-signature capture.

Submit

Compliance & Regulatory Notes

Review these notes before deploying this form in your practice.

IGF-LR3 is not FDA-approved and is prescribed off-label. Informed consent documenting the investigational nature of the therapy is required. See FSMB: https://www.fsmb.org

IGF-LR3 has potent insulin-like hypoglycemic effects. Patients must be counseled on hypoglycemia risk and monitoring protocols.

Due to IGF-1's mitogenic properties, patients with any history of malignancy should be carefully evaluated. Active cancer is a contraindication.

IGF-LR3 must be dispensed by a licensed compounding pharmacy. See FDA: https://www.fda.gov/drugs/human-drug-compounding

Want This Form Automated?

Karpa Health turns static intake forms into a fully automated clinical workflow. Branded, HIPAA-compliant, and connected to compounding pharmacies.

  • Branded intake on your website
  • AI contraindication screening
  • One-click prescribing to pharmacies
  • Automated refill management
  • E-signatures and HIPAA audit trail
  • 50-state provider network included
Book a Demo

Free 30-minute walkthrough

Sources & References

  1. FDA Human Drug Compounding Guidance
  2. FSMB Off-Label Prescribing Guidelines
  3. Endocrine Society Clinical Practice Guidelines

Frequently Asked Questions

What is the difference between IGF-LR3 and standard IGF-1?

IGF-LR3 is a modified analogue of IGF-1 with a longer half-life and greater potency. It has reduced binding to IGF-binding proteins, resulting in stronger and more prolonged activity.

Why is cancer history a contraindication for IGF-LR3?

IGF-1 and its analogues can stimulate cell proliferation through mitogenic pathways. Active malignancy or a significant history of cancer is a contraindication due to the theoretical risk of promoting tumor growth.